These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 35197452)

  • 1. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
    Ning Q; Wu D; Wang X; Xi D; Chen T; Chen G; Wang H; Lu H; Wang M; Zhu L; Hu J; Liu T; Ma K; Han M; Luo X
    Signal Transduct Target Ther; 2022 Feb; 7(1):57. PubMed ID: 35197452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune dysregulation and system pathology in COVID-19.
    Jamal M; Bangash HI; Habiba M; Lei Y; Xie T; Sun J; Wei Z; Hong Z; Shao L; Zhang Q
    Virulence; 2021 Dec; 12(1):918-936. PubMed ID: 33757410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms.
    Ahmadian E; Hosseiniyan Khatibi SM; Razi Soofiyani S; Abediazar S; Shoja MM; Ardalan M; Zununi Vahed S
    Rev Med Virol; 2021 May; 31(3):e2176. PubMed ID: 33022818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulopathy in COVID-19: Focus on vascular thrombotic events.
    Shi W; Lv J; Lin L
    J Mol Cell Cardiol; 2020 Sep; 146():32-40. PubMed ID: 32681845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications.
    Tafazoli A; Anil Kumar S; Othman M
    Platelets; 2022 Jan; 33(1):48-53. PubMed ID: 34847829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboembolic events and Covid-19.
    Ribes A; Vardon-Bounes F; Mémier V; Poette M; Au-Duong J; Garcia C; Minville V; Sié P; Bura-Rivière A; Voisin S; Payrastre B
    Adv Biol Regul; 2020 Aug; 77():100735. PubMed ID: 32773098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential mechanisms of cerebrovascular diseases in COVID-19 patients.
    Lou M; Yuan D; Liao S; Tong L; Li J
    J Neurovirol; 2021 Feb; 27(1):35-51. PubMed ID: 33534131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides: Prospects for Use in the Treatment of COVID-19.
    Khavinson V; Linkova N; Dyatlova A; Kuznik B; Umnov R
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32987757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 and Hypercoagulability.
    Sholzberg M
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
    [No Abstract]   [Full Text] [Related]  

  • 11. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
    Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
    Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
    Haji Aghajani M; Moradi O; Amini H; Azhdari Tehrani H; Pourheidar E; Rabiei MM; Sistanizad M
    J Med Virol; 2021 Sep; 93(9):5390-5395. PubMed ID: 33913549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).
    Andrew M; Jayaraman G
    Carbohydr Res; 2021 Jul; 505():108326. PubMed ID: 34015720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.
    Chen Y; Wang J; Liu C; Su L; Zhang D; Fan J; Yang Y; Xiao M; Xie J; Xu Y; Li Y; Zhang S
    Mol Med; 2020 Oct; 26(1):97. PubMed ID: 33121429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clotting disorder in severe acute respiratory syndrome coronavirus 2.
    Pujhari S; Paul S; Ahluwalia J; Rasgon JL
    Rev Med Virol; 2021 May; 31(3):e2177. PubMed ID: 33022790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm.
    Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B
    Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
    Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
    Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Impaired Inflammatory and Innate Immune Response in COVID-19.
    Park SH
    Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
    Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective.
    Lee C; Choi WJ
    Arch Pharm Res; 2021 Jan; 44(1):99-116. PubMed ID: 33398692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.